AbbVie (ABBV) IV into FDA decision on Rinvoq
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts ABBV Hot Sheet
Price: $285.64 +0.16%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.4%
Revenue Growth %: +10.0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.4%
Revenue Growth %: +10.0%
Join SI Premium – FREE
AbbVie (NYSE: ABBV) 30-day option implied volatility is at 23; compared to its 52-week range of 18 to 40 into FDA decision on Rinvoq.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA clears subcutaneous induction option for AbbVie's Skyrizi in Crohn's
- GE Vernova (GEV) call put ratio 1 call to 1 put into quarter results
- Microsoft (MSFT) call put ratio 2 calls to 1 put into quarter results
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
